Evaluation of acotiamide for the treatment of functional dyspepsia

Bibliography

• Tack J, Talley NJ. Functional dyspepsia – symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013;10(3):134-41
   PubMed Web of Science ®Google Scholar
• Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10(3):187-94
   PubMed Web of Science ®Google Scholar
• Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012;28(6):615-20
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012;9(3):132-9
   PubMed Web of Science ®Google Scholar
• McNally MA, Talley NJ. Current treatments in functional dyspepsia. Curr Treat Options Gastroenterol 2007;10(2):157-68
   PubMedGoogle Scholar
• Loldrup D, Langemark M, Hansen HJ, et al. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology (Berl) 1989;99(1):1-7
   PubMed Web of Science ®Google Scholar
• Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93(2):160-5
   PubMed Web of Science ®Google Scholar
• Sawhney MS, Prakash C, Lustman PJ, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci 2007;52(2):418-24
   PubMed Web of Science ®Google Scholar
• Lacy BE, Talley NJ, Locke GR III, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012;36(1):3-15
   PubMed Web of Science ®Google Scholar
• Moayyedi P. Dyspepsia. Curr Opin Gastroenterol 2012;28(6):602-7
   PubMed Web of Science ®Google Scholar
• Liu B, Piao X, Guo L. Effect of herbal formula xiao pi-II on functional dyspepsia. J Tradit Chin Med 2013;33(3):298-302
   PubMed Web of Science ®Google Scholar
• Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil 2010;22(6):595-9
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther 2011;336(3):791-800
   PubMed Web of Science ®Google Scholar
• Astellas Pharma, Inc. Conclusion of co-development and co-marketing agreement on a functional dyspepsia agent Z-338/YM443 in Japan with Zeria. 2008. Available from: http://www.astellas.com/en/corporate/news/detail/conclusion-of-codevelopment-an.html [Last accessed 20 June 2013]
   Google Scholar
• Zeria Pharmaceutical Co. Ltd, Astellas Pharma Inc. Approval in Japan for treating functional dyspepsia with Acofide. 2013. Available from: http://www.zacks.com/stock/news/95780/Astellas-Acofide-Approved-in-Japan [Last accessed 30 June 2013]
   Google Scholar
• Zeria Pharmaceutical Co. Ltd, Astellas Pharma, Inc. Launch of Acofide in Japan for treating functional dyspepsia. 2013. Available from: http://www.astellas.com/en/corporate/news/detail/launch-of-acofide-in-japan-for.html [Last accessed 20 June 2013]
   Google Scholar
• Furuta S, Kamada E, Omata T, et al. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol 2004;497(2):223-31
   PubMed Web of Science ®Google Scholar
• Rampe D, Roy ML, Dennis A, et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997;417(1):28-32
   PubMed Web of Science ®Google Scholar
• Oliver SD, Ward C, Ward J, et al. Z-338: phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects [abstract no. 948 plus poster]. 7th World Conference on Clinical Pharmacology and Therapeutics (CPT) and the 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT); 16 – 20 July 2000; Florence, Italy
   Google Scholar
• Zeria Pharmaceutical Co. Ltd, Astellas Pharma, Inc. Acofide tablets 100 mg: Japanese prescribing information. 2013. Available from: http://www.astellas.com/en/corporate/news/pdf/130325_2_Eg.pdf [Last accessed 18 June 2013]
   Google Scholar
• Yoshii K, Hirayama M, Nakamura T, et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. J Pharm Sci 2011;100(11):4965-73
   PubMed Web of Science ®Google Scholar
• Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther 2000;294(1):33-7
   PubMed Web of Science ®Google Scholar
• Morita H, Abe K, Ito Y, et al. Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach. Jpn J Pharmacol 2002;89(4):356-65
   PubMedGoogle Scholar
• Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res 2000;36(2):69-81
   PubMedGoogle Scholar
• Kanemoto Y, Ishibashi H, Doi A, et al. An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338. Br J Pharmacol 2002;135(6):1403-14
   PubMed Web of Science ®Google Scholar
• Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil 2012;24(6):566-74. e256
   PubMed Web of Science ®Google Scholar
• Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol 2011;666(1-3):218-25
   PubMed Web of Science ®Google Scholar
• Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008;20(9):1051-9
   PubMed Web of Science ®Google Scholar
• Akaike H, Jang II, Hori N, et al. Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. J Smooth Muscle Res 2010;46(1):31-47
   PubMedGoogle Scholar
• Zeria Pharmaceutical Co Ltd. Responding to cutting-edge medical demands. 2013. Available from: http://www.zeria.co.jp/english/comp/co_0501.html [Accessed 24 June 2013]
   Google Scholar
• Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22(6):618-e173
   PubMed Web of Science ®Google Scholar
• Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24(6):540-5. e250-1
   PubMed Web of Science ®Google Scholar
• Adam B, Liebregis T, Zschau NB, et al. Z-338 improves meal induced dyspepsia. Gastroenterology 2009;136(5 Suppl):A535
   Google Scholar
• Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61(6):821-8
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Ushijima S, et al. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 2011;84(4):261-8
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack JF, et al. Efficacy of acotiamide (Z-338) in patients with postprandial distress syndrome or overlap of epigastric pain syndrome and postprandial distress syndrome in functional dyspepsia. Gastroenterology 2011;140(5 Suppl 1):S805
   Google Scholar
• Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21(3):272-80
   PubMed Web of Science ®Google Scholar
• Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013;310(24):2640-9
   PubMed Web of Science ®Google Scholar